A Disintegrin And Metalloproteinase 12 produced by tumour cells accelerates osteosarcoma tumour progression and associated osteolysis.
暂无分享,去创建一个
F. Verrecchia | M. Padrines | D. Heymann | Y. Fortun | F. Gouin | F. Redini | J. Chesneau | Julien Taurelle | S. Georges | S. Hervouet
[1] A. Anghel,et al. Increased expression of ADAM12 and ADAM17 genes in laser-capture microdissected breast cancers and correlations with clinical and pathological characteristics. , 2012, Acta histochemica.
[2] D. Scherman,et al. Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] M. Agulnik,et al. Targeted therapies in bone sarcomas: current approach and future directions , 2011, Expert opinion on investigational drugs.
[4] Maeve Mullooly,et al. The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? , 2011, Clinical Proteomics.
[5] D. Heymann,et al. Mifamurtide for the treatment of nonmetastatic osteosarcoma , 2011, Expert opinion on pharmacotherapy.
[6] G. Moriceau,et al. Therapeutic approach of primary bone tumours by bisphosphonates. , 2010, Current pharmaceutical design.
[7] M. Sonobe,et al. A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma , 2009, Journal of surgical oncology.
[8] D. Edwards,et al. The ADAM metalloproteinases , 2008, Molecular Aspects of Medicine.
[9] S. Raza,et al. Urinary Metalloproteinases: Noninvasive Biomarkers for Breast Cancer Risk Assessment , 2008, Cancer Epidemiology Biomarkers & Prevention.
[10] Y. Okada,et al. ADAMs in cancer cell proliferation and progression , 2007, Cancer science.
[11] T. Ørntoft,et al. Molecular Profiling of ADAM12 in Human Bladder Cancer , 2006, Clinical Cancer Research.
[12] M. Bonneville,et al. Complex Interplay of Activating and Inhibitory Signals Received by Vγ9Vδ2 T Cells Revealed by Target Cell β2-Microglobulin Knockdown1 , 2006, The Journal of Immunology.
[13] D. Heymann,et al. Osteosarcoma: current status of immunotherapy and future trends (Review). , 2006, Oncology reports.
[14] J. Foidart,et al. Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC) , 2006, British Journal of Cancer.
[15] M. Harting,et al. Management of osteosarcoma pulmonary metastases. , 2006, Seminars in pediatric surgery.
[16] P. Kronqvist,et al. A role for ADAM12 in breast tumor progression and stromal cell apoptosis. , 2005, Cancer research.
[17] E. Kleinerman,et al. Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma. , 2005, Cancer research.
[18] D. Zurakowski,et al. ADAM 12 Cleaves Extracellular Matrix Proteins and Correlates with Cancer Status and Stage* , 2004, Journal of Biological Chemistry.
[19] T. Shiomi,et al. Tumorigenesis and Neoplastic Progression ADAM12 Is Selectively Overexpressed in Human Glioblastomas and Is Associated with Glioblastoma Cell Proliferation and Shedding of Heparin-Binding Epidermal Growth Factor , 2004 .
[20] K. Mark,et al. Interaction of the disintegrin and cysteine-rich domains of ADAM12 with integrin α7β1 , 2004 .
[21] S. Ferrari,et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Tomoyuki Saito,et al. Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation. , 2002, Cancer letters.
[23] L. Shultz,et al. Establishment and characterization of a new osteogenic cell line (MOS-J) from a spontaneous C57BL/6J mouse osteosarcoma. , 2002, In vivo.
[24] H. Chien,et al. Down-Regulation of Osteoblastic Cell Differentiation by Epidermal Growth Factor Receptor , 2000, Calcified Tissue International.
[25] R. Fässler,et al. The Cysteine-Rich Domain of Human Adam 12 Supports Cell Adhesion through Syndecans and Triggers Signaling Events That Lead to β1 Integrin–Dependent Cell Spreading , 2000, The Journal of cell biology.
[26] A. Zallone,et al. Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts. , 2000, Biochemical and biophysical research communications.
[27] B F Boyce,et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. , 1996, The Journal of clinical investigation.
[28] Jan-Kan Chen,et al. Differential inhibitory effects of TGF‐β on EGF‐, PDGF‐, and HBGF‐1‐stimulated MG63 human osteosarcoma cell growth: Possible involvement of growth factor interactions at the receptor and postreceptor levels , 1989, Journal of cellular physiology.
[29] E. Canalis,et al. Direct stimulation of bone resorption by epidermal growth factor. , 1980, Endocrinology.
[30] J. Couchman,et al. Cellular roles of ADAM12 in health and disease. , 2008, The international journal of biochemistry & cell biology.
[31] H. Kitano,et al. A comprehensive pathway map of epidermal growth factor receptor signaling , 2005, Molecular systems biology.
[32] Hiroshi Asanuma,et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy , 2002, Nature Medicine.
[33] J. Chirgwin,et al. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. , 2000, Critical reviews in eukaryotic gene expression.